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CD3, CD28 CO-STIMULATED SYNGENEIC T CELLS MEDIATE GVL 
AGAINST MURINE MYELOMA: THI/TCI > TH2/TC2 
Hou, ft. ~V.; Fowler, D.H. Experimented Tl:ansplm~tlftiou and bmmmol- 
ogy, NCI, Bet,bestir6 MD. 
Allogeneic Th l /Tc l  cells generated by CD3, CD28 co-stimula- 
tion mediate potent GVT effects but are limited by GVttD. To test 
whether co-stimulated Th l /Tc I  cells might mediate anti-tumor 
effects in syngeneic systems not associated with GVHD, we devel- 
oped a murine myeloma model (Balb/c [H-2 d] BMT into irradiated 
Balb/c hosts [700-850 cGy]; MOPC-315 [H 2d]tumor inoculation 
[5 x 105 ceils, i.v.]). Prior to BMT, syngeneic Balb/c splenic T cells 
were isolated, stimulated with tosylated beads conjugated with anti- 
CD3 and anti-CD28, and expanded for 6 days under T1 (rm IL-12, 
anti-IL-4) or T2 (rmIL-4) polarizing conditions. Both T1 and T2 
cultures expanded ~ 2 logs and resulted in ~ 1:1 CD4:CD8 ratio. T1 
cells secreted primarily IL-2 and IFN-v; T2 cells secreted primarily 
IL-4, IL-5, and IL-10. Recipients of BMT died of disseminated 
myeloma (mean, 19.1 days post-BMT). Adoptive transfer of TI  or 
T2 cells resulted in long-term myeloma-free survival (observation 
period >= 60 days post-BMT) in 20/22 and 10/24 cases (TI>T2, 
p=0.003). Using IFN-vdeficient Th l /Tc l  cells or CD40-deficient 
hosts, we found that T1 mediated GVL occurred independent of
T1 IFN- v (10/10 long-term survivors) or activation of host APC via 
CD40 (I0/I0 long-term survivors). Purified CD8+ TcI cells medi- 
ated a GVL effect (10/14 survivors), whereas purified CD4+ Thl  
cells did not mediate GVL (0/6 survivors). T1 survivors were pro- 
tected from subcutaneous tumor re-challenge (7/8 cases); in addi- 
tion, secondary transfer of Tl-recipient splenic T ceils protected 
BMT recipients against MOPC challenge (i0/10 cases). In conclu- 
sion, co-stimulated syngeneic Th l /Tc l  cells mediate apotent GVL 
effect hat requires the TcI component, occurs independent ofTI 
IFN- v secretion and host APC activation via CD40, and provides 
long-term immunologic memory. CD3/CD28 co-stimulation of
autologous T cells trader polarizing T1 conditions may represent an 
approach to optimize adoptive T cell therapy of nmltiple myeIoma. 
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TWO HLA-A2-RESTRICTED PEPTIDES FROM CYCLIN El AND CYCLIN 
E2 ELICIT CTL THAT KILL MYELOID LEUKEMIA CELL LINE 
Kondo, Y.; Lu, S.; WaJ~g, C.; Molldrem, tiff. Blood aJ~d Marrow 
T'ransplantatiou, M. D. AndersoJ~ Cm~cer Ceuter, Housto~h TX. 
We have previously shown that PRI, a deduced HLA-A2- 
restricted peptide derived from overexpressed proteinase 3, is a 
leukemia-associated antigen. Using the same strategy, we scanned 
the homologous proteins, cyclin El (El) and cyclin E2 (E2) using 
the HLA-A2 binding motif, since cyclin E is constitutively 
expressed in some tumor cells independent of the cell cycle and 
contribute to tumorigenesis. We first investigated whether both 
EI and E2 mRNA is overexpressed in 21 patients with leukenfia 
(11 CML (CP), 5 CML (BC), 2 AML, 2 ALL, 1 NHL) and in 12 
healthy donors by RT-PCR. Expression of E 1 was higher in 15/21 
leukemia patients compared to 5/I2 donors that expressed E1 
(p=0.01S). Expression of E2 was present in i0/21 patients but 
none of 12 donors (p=0.004). In 18/21 patients, Western blotting 
confirmed protein expression, while none of the tested donors 
(3/12) expressed proteins. The 2 nonameric peptides from E1 
(CCNE1144-1sz) and E2 (CCNE2144 152)predicted HLA-A2 bind- 
ing differed by a single amino acid at position 7. Binding was con- 
firmed using surface HLA-A2 stabilization on T2 cells and was 
similar to PR1. ~Vc next stimulated PBMCs from 7 HLA-A2 + 
donors with peptide-coated T2 cells. In 3/7 donors, CCNEl~44 
~2-stimulated CTL lines killed both CCNEl144_IS2 and 
CCNE2144 tsz-coated T2 cells but neither non-peptide-coated T2 
cells nor irrelevant peptide-coated T2 cells. In 4 of the 7 donors, 
CCNE21,4~ls2-stimulated CTL lines killed both CCNE2:44~ls2 
and CCNE1144_l~z-coated T2 cells but neither non-peptide-coat- 
ed T2 cells nor irrelevant peptide-coated T2 cells. Thus, CTLs 
specific for each peptide recognized the homologous peptide from 
the alternate protein, although the immunogenicity of each pep- 
tide was different among individuals. Moreover, one of 4 
CCNEl144~ls2-stimulated CTL lines also killed the HLA-A2 
transfected K562 leukemic ell line that overexpressed E I protein, 
but not the non-transfected K562 leukemic cell line (61.6% vs 
39.9% specific lysis at E: T 20:1). Thus, CCNEl144_lsz-specific 
CTL can distinguish leukemic ell lines from normal PBMCs. We 
conclude that E1/E2-derived peptides are potential leukemia- 
associated antigens, because E1 and E2 are highly overexpressed 
in leukemia, E1 and E2 stimulate peptide-specific CTL, and 
CCLE1144-1s2 specific CTL preferentially kill leukemic ell lines 
in an HLA-A2-restricted manner. 
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A CRITICAL ROLE FOR CCR2 IN THE DEVELOPMENT OF IDIOPATHIC 
PNEUMONIA SYNDROME AFTER ALLOGENEIC BMT 
Hildebrlmdt, G.C/; D~ze~, U.A.2; Olkiewicz, K.MJ; Erickson, N/; 
Moot'e, B.B.2; Hog~tboam, CM.S; Reddy, P.R.2; Liu, C.4; Ferrara, if.L J; 
Cooke, I~R/ 1. University of Michiga~ Caucer Center, D pt. of Pedi- 
atrics, Aml Arbo~ , MI; 2. Univel"sity of~Iichigmz, Dept. of hzte~vzal Med- 
icine, Ann ArboJ-, MI; 3. Uyziversity ofMichigau, Dept. of Pathology, Amz 
Arbor, MI; 4. Unive'rsity ofFlorida College of Medici~ze, Gaiuesville, FL. 
Idiopathic pneumonia syndrome (IPS) is a frequently fatal com- 
plication of allogeneic (allo) bone marrow transplantation (BMT). 
The pathophysiology of IPS includes both inflammatory c toldnes 
such as TNFc~, and the recruitment of donor derived T cells and 
monocytes. We hypothesized that leukocyte recruitment during 
IPS is dependent upon the expression of monocyte chemoattrac- 
tant protein-1 (MCP-1) and its primary receptor CCR2. CCR2 is 
expressed on monocytes and T cells. MCP-1 is produced in 
response to inflammatory stimuli by both immune and non- 
immune cells, and leads to the migration of CCR2+ leukocytes to 
sites of inflammation. We examined the role of CCR2:MCP 
receptor:ligand interactions in the development of IPS using an 
established murine BMT model (B6 -> B6D2FI). Lethally irradi- 
ated B6DF1 mice received BMT from either syngeneic (B6D2F1) 
or allogeneic (B6) donors. We first determined that turnover of 
donor lymphocytes and macrophages in the bronchoalveolar space 
was complete by day 14 and 28 after allo BMT respectively. Next, 
we found that whole lung MCP~I mRNA expression was signifi- 
cantly increased from week 1 to 6 in allo BMT recipients com- 
pared to syngeneic ontrols. This correlated with increases in 
CCR2 mRNA (weeks 2 to 6) and with BAL MCP-1 protein levels 
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